Want to see SE:XSPRAY full AI Analyst Report?
XSPRAY Stock Chart & Stats
kr10.74
kr0.28(1.83%)
At close: 4:00 PM EDT
kr10.74
kr0.28(1.83%)
Day’s Range― - ―
52-Week Rangekr9.06 - kr35.15
Previous CloseN/A
Volume28.64K
Average Volume (3M)84.96K
Market Cap
kr521.58M
Enterprise Valuekr645.43M
Total Cash (Recent Filing)kr179.91M
Total Debt (Recent Filing)kr147.30M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.86
Shares Outstanding47,416,573
10 Day Avg. Volume113,406
30 Day Avg. Volume84,962
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-5.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.2
Revenue Forecast (FY)kr95.00M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthSubstantial equity relative to debt gives Xspray a comparatively moderate leverage position for an early-stage biotech. This provides more balance-sheet support for continued development than a highly indebted structure, although it does not eliminate the need to fund ongoing operating losses.
HyNap Technology PlatformThe HyNap platform targets established medicines where formulation improvements may create differentiated or bioequivalent products. A reusable technology approach can support multiple development opportunities and partnership or licensing potential if candidates achieve regulatory and commercial milestones.
Improving Loss TrendThe reduction in net losses from the 2024 trough indicates some improvement in financial performance, even though profitability remains weak. If maintained, lower losses could extend the company’s financial runway and reduce the pace at which external capital is required to support development.
Bears Say
No Revenue And Persistent LossesXspray has not yet demonstrated commercial revenue generation and remains deeply unprofitable. Until a product reaches approval and market uptake, the company lacks an operating revenue base to absorb development costs, making its financial performance highly dependent on future commercialization progress.
Sustained Cash BurnPersistent negative operating and free cash flow means the business is consuming cash rather than funding its activities internally. Continued development therefore depends on financing or partnership inflows, which can constrain strategic flexibility and expose operations to funding requirements over the coming quarters.
Rising Leverage And Negative ReturnsAlthough leverage remains moderate, debt has increased materially from earlier years while returns on equity remain consistently negative. This combination signals that capital is not yet producing positive returns and could become more burdensome if losses persist or access to financing becomes less favorable.
Xspray Pharma AB News
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr9.06 and its highest was kr35.15 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr521.58M.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Nov 04, 2026 which is in 21 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Aug 05, 2026. The company reported -kr0.868 earnings per share for the quarter.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 47,416,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -kr0.868 in its last earnings report. Following the earnings report the stock price went down -6.988%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
Technical Analysis
Camurus AB
―
Vicore Pharma Holding AB
―
Xbrane Biopharma AB
―
Spago Nanomedical AB
―
Bio-Works Technologies AB
―